摘要
Background Non-valvular atrial fibrillation is associated with an increased risk of ischemic stroke; however, the appropriate intensity of anticoagulation therapy for Chinese patients has not been determined. The purpose of this study was to compare the safety and the efficacy of standard-intensity warfarin therapy, low-intensity warfarin therapy, and aspirin therapy for the prevention of ischemic events in Chinese patients with non-valvular atrial fibrillation （NVAF）. Methods A total of 786 patients from 75 Chinese hospitals were enrolled in this study and randomized into three therapy groups： standard-intensity warfarin （international normalized ratio （INR） 2.1 to 2.5） group, low-intensity warfarin （INR 1.6 to 2.0） group and aspirin （200 mg per day） group. All patients were evaluated by physicians at 1,3, 6, 9, 12, 15, 18, 21 and 24 months after randomization to obtain a patient questionnaire, physical examination and related laboratory tests. Results The annual event rates of ischemic stroke, transient ischemic attack （TIA） or systemic thromboembolism were 2.6%, 3.1% and 6.9% in the standard-intensity warfarin, low-intensity warfarin and aspirin groups, respectively （P=0.027）. Thromboembolic event rates in both warfarin groups were significantly lower than that in the aspirin group （P=0.018, P=0.044）, and there was no significant difference between the two warfarin groups. Severe hemorrhagic events occurred in 15 patients, 7 （2.6%） in the standard-intensity warfarin group, 7 （2.4%） in the low-intensity warfarin group and 1 （0.4%） in the aspirin group. The severe hemorrhagic event rates in the warfarin groups were higher than that in the aspirin group, but the difference did not reach statistical significance （P=0.101）. The mild hemorrhagic and total hemorrhagic event rates in the warfarin groups （whether in the standard-intensity warfarin group or low-intensity warfarin group） were much higher than that in the aspirin group with the annual event rates of total hemorrhages of 10.2%, 7.6% and 2.2%, respectively, in the 3 groups （P=0.001）. Furthermore, there was no significant difference in all cause mortality among the three study groups. Conclusion In Chinese patients with NVAF, the warfarin therapy （INR 1.6-2.5） for the prevention of thromboembolic events was superior to aspirin.
Background Non-valvular atrial fibrillation is associated with an increased risk of ischemic stroke; however, the appropriate intensity of anticoagulation therapy for Chinese patients has not been determined. The purpose of this study was to compare the safety and the efficacy of standard-intensity warfarin therapy, low-intensity warfarin therapy, and aspirin therapy for the prevention of ischemic events in Chinese patients with non-valvular atrial fibrillation （NVAF）. Methods A total of 786 patients from 75 Chinese hospitals were enrolled in this study and randomized into three therapy groups： standard-intensity warfarin （international normalized ratio （INR） 2.1 to 2.5） group, low-intensity warfarin （INR 1.6 to 2.0） group and aspirin （200 mg per day） group. All patients were evaluated by physicians at 1,3, 6, 9, 12, 15, 18, 21 and 24 months after randomization to obtain a patient questionnaire, physical examination and related laboratory tests. Results The annual event rates of ischemic stroke, transient ischemic attack （TIA） or systemic thromboembolism were 2.6%, 3.1% and 6.9% in the standard-intensity warfarin, low-intensity warfarin and aspirin groups, respectively （P=0.027）. Thromboembolic event rates in both warfarin groups were significantly lower than that in the aspirin group （P=0.018, P=0.044）, and there was no significant difference between the two warfarin groups. Severe hemorrhagic events occurred in 15 patients, 7 （2.6%） in the standard-intensity warfarin group, 7 （2.4%） in the low-intensity warfarin group and 1 （0.4%） in the aspirin group. The severe hemorrhagic event rates in the warfarin groups were higher than that in the aspirin group, but the difference did not reach statistical significance （P=0.101）. The mild hemorrhagic and total hemorrhagic event rates in the warfarin groups （whether in the standard-intensity warfarin group or low-intensity warfarin group） were much higher than that in the aspirin group with the annual event rates of total hemorrhages of 10.2%, 7.6% and 2.2%, respectively, in the 3 groups （P=0.001）. Furthermore, there was no significant difference in all cause mortality among the three study groups. Conclusion In Chinese patients with NVAF, the warfarin therapy （INR 1.6-2.5） for the prevention of thromboembolic events was superior to aspirin.
